<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tyurin AP</submitter><funding>Russian Academy of Sciences</funding><funding>National Natural Science Foundation of China</funding><funding>Russian Foundation for Basic Research</funding><pagination>667-675</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6071864</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(4)</volume><pubmed_abstract>The study of an archived sample of crystallomycin complex using HPLC, ESI HRMS, and 2D NMR showed that two major components of the antibiotic, compounds &lt;b>1&lt;/b> and &lt;b>2&lt;/b>, are lipopeptides having the same peptide core, Asp1-cyclo(Dab2-Pip3-MeAsp4-Asp5-Gly6-Asp7-Gly8-Dab9-Val10-Pro11-), &lt;i>N&lt;/i>-acylated either with Δ&lt;sup>3&lt;/sup>-iso-tetradecenoyl or Δ&lt;sup>3&lt;/sup>-anteiso-pentadecenoyl that are identical to aspartocins C and B, respectively. According to the 2D NMR study, compound &lt;b>2&lt;/b> in DMSO solution exists as a mixture of four conformers. The producing strain was identified as &lt;i>Streptomyces griseorubens&lt;/i>. Compounds &lt;b>1&lt;/b> and &lt;b>2&lt;/b> have considerable Ca&lt;sup>2+&lt;/sup>-dependent activity against Gram-positive bacteria including five MRSA strains.</pubmed_abstract><journal>MedChemComm</journal><pubmed_title>Crystallomycin revisited after 60 years: aspartocins B and C.</pubmed_title><pmcid>PMC6071864</pmcid><funding_grant_id>81611530716</funding_grant_id><funding_grant_id>17-53-53130</funding_grant_id><pubmed_authors>Grammatikova NE</pubmed_authors><pubmed_authors>Efimenko TA</pubmed_authors><pubmed_authors>Shuvalov MV</pubmed_authors><pubmed_authors>Malanicheva IA</pubmed_authors><pubmed_authors>Sun C</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Shenkarev ZO</pubmed_authors><pubmed_authors>Prokhorenko IA</pubmed_authors><pubmed_authors>Korshun VA</pubmed_authors><pubmed_authors>Tyurin AP</pubmed_authors><pubmed_authors>Paramonov AS</pubmed_authors><pubmed_authors>Solyev PN</pubmed_authors><pubmed_authors>Alferova VA</pubmed_authors><pubmed_authors>Efremenkova OV</pubmed_authors><pubmed_authors>Terekhova LP</pubmed_authors></additional><is_claimable>false</is_claimable><name>Crystallomycin revisited after 60 years: aspartocins B and C.</name><description>The study of an archived sample of crystallomycin complex using HPLC, ESI HRMS, and 2D NMR showed that two major components of the antibiotic, compounds &lt;b>1&lt;/b> and &lt;b>2&lt;/b>, are lipopeptides having the same peptide core, Asp1-cyclo(Dab2-Pip3-MeAsp4-Asp5-Gly6-Asp7-Gly8-Dab9-Val10-Pro11-), &lt;i>N&lt;/i>-acylated either with Δ&lt;sup>3&lt;/sup>-iso-tetradecenoyl or Δ&lt;sup>3&lt;/sup>-anteiso-pentadecenoyl that are identical to aspartocins C and B, respectively. According to the 2D NMR study, compound &lt;b>2&lt;/b> in DMSO solution exists as a mixture of four conformers. The producing strain was identified as &lt;i>Streptomyces griseorubens&lt;/i>. Compounds &lt;b>1&lt;/b> and &lt;b>2&lt;/b> have considerable Ca&lt;sup>2+&lt;/sup>-dependent activity against Gram-positive bacteria including five MRSA strains.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Apr</publication><modification>2026-04-30T23:04:10.382Z</modification><creation>2019-06-06T19:56:37Z</creation></dates><accession>S-EPMC6071864</accession><cross_references><pubmed>30108957</pubmed><doi>10.1039/c8md00002f</doi></cross_references></HashMap>